Genprex to Present TUSC2 Gene Research in November

The company will share data on cellular-resilience programs at the Gerontological Society of America's 2026 meeting.

Updated on Oct. 28, 2026 in Life Sciences

Genprex to Present TUSC2 Gene Research in November

Live Poll

Should pharmaceutical companies prioritize researching aging processes alongside their existing cancer and diabetes treatment programs?

Genprex is set to present findings on its TUSC2 gene therapy at the Gerontological Society of America 2026 Annual Scientific Meeting on November 4, 2026. The presentation explores how this therapy may influence cellular-resilience programs.

Why it matters

The research, conducted in collaboration with Meharry Medical College, aims to investigate potential therapeutic applications for the drug REQORSA beyond its current oncology focus.

The session presentation features Abstract ID 2489375 and is scheduled for 6:00 - 7:15 p.m. ET. The study focuses on TUSC2 gene therapy and its specific role in mitochondrial biology, cellular metabolism, and stress-response pathways.

The players

Genprex

This clinical-stage gene therapy company is headquartered in Austin, Texas, and focuses on developing novel therapies for cancer and other diseases.

Meharry Medical College

Based in Nashville, Tennessee, this private, historically Black academic health science center partners on research regarding TUSC2 gene biology.

Mark S. Berger

He serves as the Chief Medical Officer of Genprex and leads the company's clinical research efforts.

The details

The research stems from a 2024 collaboration between Genprex and Meharry Medical College to study TUSC2 gene biology and its molecular association with aging. Findings from the poster are expected to be available on the Genprex website after the session concludes.

2024: Genprex and Meharry Medical College launched their sponsored research collaboration.
November 4, 2026: Genprex presents the research during the Late Breaking Poster Session I.
November 4-7, 2026: The Gerontological Society of America 2026 Annual Scientific Meeting occurs in National Harbor, Maryland.

The Big Picture

This research extends the scope of the REQORSA drug development program by evaluating its biological utility in aging-related cellular resilience. It signals a move to test existing gene therapy mechanisms in new physiological domains outside of traditional oncology.

The findings could eventually lead to new medical treatments that address cellular decline or stress-response pathways in patients. Future commercialization remains dependent on the success of subsequent clinical and laboratory trials.

The takeaway

This presentation illustrates how gene therapy researchers are increasingly looking toward aging biology to find new applications for existing technology. Investors and patients can monitor the Genprex website after the conference for public access to the research poster.